Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Written by Jeffrey Neal Johnson. Date Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
In the next 3 minutes…
James Altucher – legendary investor and venture capitalist…
And someone who’s known for playing his cards “close to the vest”…
Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO… Click here to watch this short 3-minute video now.
Abbott Laboratories’ stock price recently touched a 52-week low, closing just above $100 in late March. The sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation shows a potential disconnect between market sentiment and operational reality, raising a critical question: Is the market’s pessimism justified, or has a significant value opportunity emerged for long-term investors? Separating the Signal From the NoiseAbbott’s recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, driven mainly by market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the issue and outlined a clear turnaround plan. CEO Robert B. Ford detailed pricing and promotion initiatives and a pipeline of at least eight new product launches in 2026 to reignite volume, forecasting a return to growth in the second half of the year. The second factor is external and broader in scope: a rotation of capital across the market. In periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector and into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. This broad trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment works toward a short-term recovery, Abbott's core businesses remain robust, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott's diversified model provides a powerful counterbalance to the isolated weakness in nutrition; the company’s true health shows up in these high-performing areas.
Medical Devices: The Medical Devices division is firing on multiple cylinders, driven by market-leading innovation across critical care areas. Diabetes Care: The FreeStyle Libre continuous glucose monitor (CGM) franchise continues to be a growth phenomenon. The product, which lets users track glucose without routine fingersticks, generated over $7.5 billion in sales in 2025 and remains a primary driver of Abbott's success. Cardiovascular Leadership: Abbott is a dominant player in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, and its Structural Heart business posted strong organic growth of 8.7%. This strength stems from a portfolio of best-in-class products, such as MitraClip and TriClip, and a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also making a major strategic play to secure future growth through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. The deal would immediately position Abbott as a leader in the expanding, multi-billion-dollar cancer-diagnostics market, adding a new high-growth vertical set to contribute meaningfully to revenue over time. That bullish view is shared by Wall Street. Analysts maintain a Moderate Buy consensus rating on the stock, and the average 12-month price target is $135.47 — implying potential upside of more than 30% from current levels. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend remains a central attraction. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a deep commitment to returning capital to shareholders across market cycles. The recent drop in Abbott’s stock price benefits new investors by boosting the dividend yield: at current levels Abbott yields about 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend payout ratio is about 68% of earnings, and the dividend represents only roughly 37% of cash flow — indicating Abbott generates ample cash to cover payments with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment appears disconnected from Abbott's business reality. Temporary headwinds in a single division and broad market rotation have pressured the stock, but Abbott's fundamental growth engines are accelerating. Its dominant Medical Devices division continues to deliver, the dividend remains durable, and catalysts like the Exact Sciences acquisition could broaden and accelerate growth. For investors with a long-term horizon, the present valuation looks like a notable gap between price and intrinsic value — an opportunity worth considering. |
